Alirocumab Market Report 2026

Alirocumab Market Overview

• Alirocumab market size has reached to $2.1 billion in 2025 • Expected to grow to $3.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: The Increasing Prevalence Of Cardiovascular Diseases Is Driving The Market Due To Growing Rising Demand For Effective Lipid-Lowering Therapies To Manage Cardiovascular Risk And Complications • Market Trend: Pediatric Indication Expansion Driving Biologic Adoption In Lipid Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alirocumab Market?

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin kexin type 9, a regulatory protein involved in cholesterol metabolism, thereby enhancing the liver’s ability to remove low-density lipoprotein cholesterol from the bloodstream and significantly lowering circulating cholesterol levels through targeted biological interaction. It is primarily used in the management of hypercholesterolemia and cardiovascular risk reduction, particularly in patients who require additional lipid-lowering beyond standard therapies or who exhibit intolerance or inadequate response to conventional treatment approaches. The main indications of alirocumab include familial hypercholesterolemia, atherosclerotic cardiovascular disease, secondary hyperlipidemia, and high cardiovascular risk patients. Familial hypercholesterolemia refers to a genetic condition characterized by extremely high levels of low-density lipoprotein cholesterol, increasing the risk of early cardiovascular disease. The administration route includes subcutaneous injection and self-administration and is used across patient demographics including geriatric, pediatric, and gender-based groups. The treatment line includes first-line treatment and second-line treatment, and it is distributed through hospitals, clinics, online pharmacies, retail pharmacies, and other distribution channels.

What Is The Alirocumab Market Growth Forecast?

The alirocumab market size is expected to see rapid growth in the next few years.It will grow to $3.48 billion by 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging global population growth, expansion of pcsk9 inhibitor pipeline, increasing reimbursement coverage for biologics, growth in home-based self-administration therapies, expansion of cardiovascular preventive care programs.Major trends in the forecast period include increasing adoption of pcsk9 inhibitor therapies, rising prevalence of statin intolerance patients, expansion of cardiovascular risk screening programs, growth in monoclonal antibody-based lipid lowering therapies, rising demand for combination lipid lowering regimens.

Global Alirocumab Market Segmentation

1) By Indication: Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Secondary Hyperlipidemia, High Cardiovascular Risk Patients 2) By Administration Route: Subcutaneous Injection, Self-Administration 3) By Patient Demographics: Geriatric, Pediatric, Gender-Based 4) By Treatment Line: First-Line Treatment, Second-Line Treatment 5) By Distribution Channel: Hospitals, Clinics, Online Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Familial Hypercholesterolemia: Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia 2) By Atherosclerotic Cardiovascular Disease: Coronary Artery Disease, Peripheral Artery Disease, Cerebrovascular Disease 3) By Secondary Hyperlipidemia: Diabetes Induced Hyperlipidemia, Obesity Related Hyperlipidemia, Hypothyroidism Induced Hyperlipidemia 4) By High Cardiovascular Risk Patients: Hypertension Patients, Smokers At Risk, Elderly Population At Risk, Metabolic Syndrome Patients

What Are The Drivers Of The Alirocumab Market?

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the alirocumab industry going forward.Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, cerebrovascular disease, and heart failure, which collectively impair the efficient circulation of blood and oxygen throughout the body.A key factor driving the increasing prevalence of cardiovascular diseases is the widespread adoption of sedentary lifestyles, as reduced physical activity contributes to metabolic dysfunction, promotes the accumulation of excess body fat, and accelerates the development of risk conditions such as hypertension and dyslipidemia, thereby significantly elevating the likelihood of cardiovascular complications over time.Alirocumab effectively lowers low-density lipoprotein cholesterol levels through proprotein convertase subtilisin or kexin type 9 inhibition, thereby helping to mitigate cardiovascular risk and manage disease progression in populations increasingly affected by these conditions.For instance, in June 2024, according to the data published by the American Heart Association Inc., a US-based non-profit organization, the prevalence of cardiovascular disease in the United States is projected to rise from approximately 50% of adults currently to 61% by 2050.Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the alirocumab industry. The rising adoption of personalized medicine approaches is expected to drive the growth of the Alirocumab industry going forward.Personalized medicine refers to a medical approach that tailors treatment strategies to individual patient characteristics, including genetic profile, biomarker status, lifestyle, and disease-specific factors, with the objective of improving therapeutic efficacy and minimizing adverse effects.A key factor driving the rising adoption of personalized medicine approaches is the increasing integration of genomic insights into clinical practice, as advancements in genetic profiling enable healthcare providers to identify disease predispositions and treatment responsiveness more precisely, thereby facilitating more targeted and effective therapeutic decisions.Alirocumab supports personalized medicine by offering a targeted lipid-lowering therapy specifically beneficial for patients with genetic lipid disorders or those inadequately managed with conventional treatments, thereby enhancing individualized cardiovascular risk management.For instance, in February 2024, according to a report by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, more than one-third of new drug approvals by the U.S.Food and Drug Administration have consistently been personalized therapies for four consecutive years through 2023, with approvals in 2023 including 16 rare disease treatments (up from six in 2022), alongside seven oncology drugs and three targeting other conditions.Therefore, the rising adoption of personalized medicine approaches is driving the growth of the Alirocumab industry.

Key Players In The Global Alirocumab Market

Major companies operating in the alirocumab market are Sanofi S. A., Regeneron Pharmaceuticals Inc.

Global Alirocumab Market Trends and Insights

Major companies operating in the alirocumab market are focusing on developing innovative products, such as expanded indication biologics to broaden patient eligibility and enhance early-stage disease management. An expanded indication biologic is a therapeutic agent that receives regulatory approval for use in additional patient populations or disease conditions beyond its original indication. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, announced U. S. Food and Drug Administration approval for Praluent. This development extends the use of alirocumab to pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, enabling earlier intervention in genetically predisposed individuals. The approval strengthens preventive cardiovascular care by improving low-density lipoprotein cholesterol management and expanding the therapy’s clinical and commercial scope.

Regional Insights

North America was the largest region in the alirocumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Alirocumab Market?

The alirocumab market consists of sales of anticoagulants, blood-thinning medications, anti-hypertensive drugs, and high-dose ophthalmology biologics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Alirocumab Industry?

The alirocumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alirocumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Alirocumab Market Report 2026?

The alirocumab market research report is one of a series of new reports from The Business Research Company that provides alirocumab market statistics, including alirocumab industry global market size, regional shares, competitors with a alirocumab market share, detailed alirocumab market segments, market trends and opportunities, and any further data you may need to thrive in the alirocumab industry. This alirocumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.